How Biogen Inc. Makes Most of Its Money
Biogen (NASDAQ: BIIB) recorded $2.38 billion in product revenue in the first quarter -- a nice haul for a large biotech -- but 40% of its sales came from its top-selling multiple-sclerosis drug Tecfidera.
Drug
First-Quarter 2017 Sales
Source: Fool.com
Gilead Sciences Inc Stock
€62.43
1.380%
With 12 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
As a result the target price of 86 € shows a positive potential of 37.75% compared to the current price of 62.43 € for Gilead Sciences Inc.
